We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
Read MoreHide Full Article
On Oct 18, 2017, we issued an updated report on ImmunoGen, Inc. .
ImmunoGen is a development-stage biotechnology company, focused on developing targeted cancer therapeutics, using its proprietary antibody-drug conjugate (ADC) technology.
ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine. The candidate is currently in a phase III study (FORWARD I) as a single-agent therapy for treating patients with platinum-resistant ovarian cancer, whose tumors express high or medium levels of FR alpha. Additionally, they have received up to three prior treatment regimens. Successful development and subsequent approval will be a huge boost to the company as ovarian cancer market represents a huge potential.
Notably, combination regimens with mirvetuximab soravtansine in ovarian cancer are in the phase Ib/II FORWARD II study. The trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche’s Avastin and Merck’s Keytruda. ImmunoGen reported initial data from the FORWARD II study in May, demonstrating the candidate to have potential to complement currently available therapies for the indication.
Notably, mirvetuximab soravtansine enjoys an Orphan Drug status in both the United States and the EU for treatment of ovarian cancer.
Although the platinum-resistant ovarian cancer market provides immense commercial potential, ImmunoGen is set to face intense competition upon approval from established products like Roche’s Avastin and Johnson & Johnson’s (JNJ - Free Report) Doxil. Also, several companies are working on to introduce treatments to the market, targeting this disease.
Apart from mirvetuximab soravtansine, ImmunoGen is working to develop a couple of other candidates, including IMGN779 and IMGN632. Notably, IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia with data expected later this year. On the other hand, the company plans to move IMGN632 into clinical development before the year-end to treat hematological malignancies including acute myeloma leukemia (AML).
ImmunoGen has agreements with several big healthcare companies including Amgen Inc., Bayer, Eli Lilly and Company (LLY - Free Report) , Novartis (NVS - Free Report) , Roche, Sanofi and Takeda. These contracts in turn allow other companies to use ImmunoGen’s ADC technology and provide it with funds in the form of license and milestone fees, royalties, clinical materials revenue and R&D (research and development) support fees.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
On Oct 18, 2017, we issued an updated report on ImmunoGen, Inc. .
ImmunoGen is a development-stage biotechnology company, focused on developing targeted cancer therapeutics, using its proprietary antibody-drug conjugate (ADC) technology.
ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine. The candidate is currently in a phase III study (FORWARD I) as a single-agent therapy for treating patients with platinum-resistant ovarian cancer, whose tumors express high or medium levels of FR alpha. Additionally, they have received up to three prior treatment regimens. Successful development and subsequent approval will be a huge boost to the company as ovarian cancer market represents a huge potential.
Notably, combination regimens with mirvetuximab soravtansine in ovarian cancer are in the phase Ib/II FORWARD II study. The trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche’s Avastin and Merck’s Keytruda. ImmunoGen reported initial data from the FORWARD II study in May, demonstrating the candidate to have potential to complement currently available therapies for the indication.
Notably, mirvetuximab soravtansine enjoys an Orphan Drug status in both the United States and the EU for treatment of ovarian cancer.
Although the platinum-resistant ovarian cancer market provides immense commercial potential, ImmunoGen is set to face intense competition upon approval from established products like Roche’s Avastin and Johnson & Johnson’s (JNJ - Free Report) Doxil. Also, several companies are working on to introduce treatments to the market, targeting this disease.
Apart from mirvetuximab soravtansine, ImmunoGen is working to develop a couple of other candidates, including IMGN779 and IMGN632. Notably, IMGN779 is being evaluated in a phase I study for treating acute myeloid leukemia with data expected later this year. On the other hand, the company plans to move IMGN632 into clinical development before the year-end to treat hematological malignancies including acute myeloma leukemia (AML).
ImmunoGen has agreements with several big healthcare companies including Amgen Inc., Bayer, Eli Lilly and Company (LLY - Free Report) , Novartis (NVS - Free Report) , Roche, Sanofi and Takeda. These contracts in turn allow other companies to use ImmunoGen’s ADC technology and provide it with funds in the form of license and milestone fees, royalties, clinical materials revenue and R&D (research and development) support fees.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>